CYDY News and Press, CytoDyn Inc From 09/20/20

VANCOUVER, Washington, Sept. 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY ), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, annou...

CytoDyn ( OTCQB:CYDY -16.4% ) is down on average volume on the heels of its  conference call  updating its activities related to leronlimab. Key points: More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

Japanese High In 1989, the Japanese Nikkei hit 38,916. It was a time of craziness. The Emperor's palace was valued at equal to all of the real estate in California. Such prices are unsustainable. The Nikkei 30 years out sits at 23,205. Someday, the high point of the Nikkei will be surpassed,...

CytoDyn Inc. ( OTCQB:CYDY ) continues to be a target for short-sellers who continue to torpedo the bull thesis with weak ammunition and dreadful aim. Despite some critical hits, the bull juggernaut remains afloat and is still on course to commercialization. Captain and CEO Nader Pourhassan con...

VANCOUVER, Washington, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...

Notes from today's update from CytoDyn ( OTCQB:CYDY ) on its COVID-19 activities related to leronlimab: More news on: CytoDyn Inc., Healthcare stocks news, Stocks on the move, Read more ...

U.S. FDA schedules Type A meeting with CytoDyn to discuss BLA filing for HIV    VANCOUVER, Washington, Sept. 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 a...

Leading experts in the fields of HIV, Oncology, Rheumatology, and NASH join together to facilitate the best approaches to utilize multiple opportunities for leronlimab VANCOUVER, Washington, Sept. 01, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , ("CytoDyn" or the "Company"...

CytoDyn advances enrolment in Phase 3 COVID-19 trial CytoDyn Inc. ( CYDY ) announced that it has completed the enrollment for Phase 3 trial for COVID-19 patients with severe-to-critical symptoms. The trial is now eligible for an interim analysis following the 28-day phase. Leronlimab (PR...

CytoDyn ( OTCQB:CYDY ) will host a conference call on Wednesday, September 2, at 4:00 pm ET to update investors on all of its regulatory and clinical initiatives including its activities related to leronlimab in COVID-19. More news on: CytoDyn Inc., Healthcare stocks news, Read mor...